文献速递产科

静脉补钙减少产时剖宫产分娩失血:一项随机对照试验

Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Delivery: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2023-11-03

这项单中心、区组随机、安慰剂对照、双盲优劣性试验纳入120名34周及以上、产程中暴露缩宫素后需产时剖宫产者,比较断脐后预防性给予1克静脉氯化钙与生理盐水安慰剂对失血量的影响。主要分析中两组失血量无统计学差异(中位数840 mL vs 1051 mL,平均减少211 mL,95%CI -33至410),但在计划亚组分析中氯化钙显著减少失血量约356 mL(95%CI 159-515)。作者认为该药值得未来研究作为减少产后出血的新策略。

要点

  • 主要分析中预防性静脉氯化钙未显著减少产时剖宫产失血量(平均减少211 mL,95%CI -33至410)。
  • 计划亚组分析排除外科记录的非宫缩乏力性出血后,氯化钙减少失血量356 mL(95%CI 159-515)。
  • 两组报告副作用发生率相似(氯化钙组38% vs 安慰剂组42%)。

核心结论

  • 产时剖宫产断脐后预防性给予静脉氯化钙在主要分析中未显著减少失血量。
  • 在计划亚组分析中,氯化钙输注显著减少失血量约350 mL。
  • 作者认为该廉价且室温稳定的药物值得未来研究作为减少产后出血的新治疗策略。

研究设计与样本

  • 单中心、区组随机、安慰剂对照、双盲优劣性试验,比较1克静脉氯化钙与生理盐水安慰剂对剖宫产失血量的影响。
  • 纳入34周及以上、产程中暴露缩宫素后需产时剖宫产的产妇。
  • 钙剂或生理盐水安慰剂在断脐后1分钟开始输注10分钟,并同时给予缩宫素标准治疗。
  • 计划纳入120名患者,以在计划亚组分析中显示失血量减少200 mL,假设非宫缩乏力性出血发生率高达40%(80%把握度,α<0.05)。
  • 2022年4月至2023年3月期间,828名临产产妇知情同意,最终纳入120名参与者。

主要发现

  • 主要结局失血量中位数:氯化钙组840 mL(n=60) vs 安慰剂组1051 mL(n=60),无统计学差异(平均减少211 mL,95%CI -33至410)。
  • 计划亚组分析(氯化钙组n=39,安慰剂组n=40)排除外科记录的非宫缩乏力性出血后,氯化钙减少失血量356 mL(95%CI 159-515)。
  • 报告副作用发生率两组相似:氯化钙组38% vs 安慰剂组42%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether prophylactic administration of 1 g of intravenous calcium chloride after cord clamping reduces blood loss from uterine atony during intrapartum cesarean delivery. METHODS: This single-center, block-randomized, placebo-controlled, double-blind superiority trial compared the effects of 1 g intravenous calcium chloride with those of saline placebo control on blood loss at cesarean delivery. Parturients at 34 or more weeks of gestation requiring intrapartum cesarean delivery after oxytocin exposure in labor were enrolled. Calcium or saline placebo was infused over 10 minutes beginning 1 minute after umbilical cord clamping in addition to standard care with oxytocin. The primary outcome was quantitative blood loss, analyzed by inverse Gaussian regression. Planned subgroup analysis excluded nonatonic bleeding, such as hysterotomy extension, arterial bleeding, and occult placenta accreta. We planned to enroll 120 patients to show a 200-mL reduction in quantitative blood loss in planned subgroup analysis, assuming up to 40% incidence of nonatonic bleeding (80% power, α<0.05). RESULTS: From April 2022 through March 2023, 828 laboring parturients provided consent and 120 participants were enrolled. Median blood loss was 840 mL in patients allocated to calcium chloride (n=60) and 1,051 mL in patients allocated to placebo (n=60), which was not statistically different (mean reduction 211 mL, 95% CI -33 to 410). In the planned subgroup analysis (n=39 calcium and n=40 placebo), excluding cases of surgeon-documented nonatonic bleeding, calcium reduced quantitative blood loss by 356 mL (95% CI 159-515). Rates of reported side effects were similar between the two groups (38% calcium vs 42% placebo). CONCLUSION: Prophylactic intravenous calcium chloride administered during intrapartum cesarean delivery after umbilical cord clamping did not significantly reduce blood loss in the primary analysis. However, in the planned subgroup analysis, calcium infusion significantly reduced blood loss by approximately 350 mL. These data suggest that this inexpensive and shelf-stable medication warrants future study as a novel treatment strategy to decrease postpartum hemorrhage, the leading global cause of maternal morbidity and mortality. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT05027048.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ansari JR, Yarmosh A, Michel G, et al. Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol. 2023. PMID: 37917943. doi:10.1097/AOG.0000000000005441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。